Company profile: Quest PharmaTech
1.1 - Company Overview
Company description
- Provider of antibody-based immunotherapeutic products for cancer and photodynamic therapy technology for oncology and dermatology, including Oregovomab, an antibody-based immunotherapy in clinical trials for ovarian cancer, and truncated MUC16-targeting Mab AR 9.6 as a theranostic agent.
Products and services
- Oregovomab: A clinical-stage, antibody-based immunotherapeutic engineered to treat ovarian cancer, currently undergoing clinical trials for ovarian cancer treatment
- Photodynamic Therapy technology: A photodynamic-class technology platform the company owns, delivering photodynamic therapy for oncology and dermatology applications
- Truncated MUC16 Targeting Mab AR 9.6: A theranostic-class agent targeting truncated MUC16 for cancer treatment, architected as an antibody-based product in oncology
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Quest PharmaTech
ImCheck Therapeutics
HQ: France
Website
- Description: Provider of immunomodulatory antibody therapies and discovery services targeting cancer and immune-related diseases, including BTN3A monoclonal antibodies that modulate γ9δ2/γ9Vδ2 T cells: ICT01 to activate against advanced solid tumors; ICT41 to activate for viral, bacterial, and parasitic infections; and ICT21 to antagonize dysfunctional activation in autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImCheck Therapeutics company profile →
Trubion
HQ: United States
Website
- Description: Provider of biopharmaceutical product candidates for autoimmune diseases and cancer, developing novel single-chain polypeptide proteins built with its SMIP custom drug assembly technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trubion company profile →
PhosImmune
HQ: United States
Website
- Description: Provider of clinical-stage therapeutic cancer vaccines enabled by a library of unique, aberrantly phosphorylated tumor antigens (PTAs) directly implicated in metastasis, addressing the need for high-quality tumor antigens for use in new and more effective cancer vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PhosImmune company profile →
Sutro Biopharma
HQ: United States
Website
- Description: Provider of protein therapeutics leveraging OCFS and XpressCF cell-free protein synthesis, with an ADC pipeline: luveltamab tazevibulin (luvelta) targeting folate receptor alpha in clinical studies for platinum-resistant ovarian cancer; STRO-003 (ROR1-targeting) under a global licensing agreement with potential milestones and royalties; STRO-004 (tissue factor-targeting) planned for 2025 IND; plus sustainability efforts and a summer internship program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sutro Biopharma company profile →
Opexa Therapeutics
HQ: United States
Website
- Description: Provider of patient-specific immunotherapies for the treatment of multiple sclerosis; its lead candidate, Tcelna, is a personalized T-cell immunotherapy in Phase IIb clinical development (the Abili-T trial).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Opexa Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Quest PharmaTech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Quest PharmaTech
2.2 - Growth funds investing in similar companies to Quest PharmaTech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Quest PharmaTech
4.2 - Public trading comparable groups for Quest PharmaTech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →